Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
54,711,345
-
Number of holders
-
96
-
Total 13F shares, excl. options
-
43,943,299
-
Shares change
-
-2,565,409
-
Total reported value, excl. options
-
$173,133,829
-
Value change
-
-$18,481,683
-
Put/Call ratio
-
39%
-
Number of buys
-
41
-
Number of sells
-
-56
-
Price
-
$3.94
Significant Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) as of Q3 2023
122 filings reported holding STOK - Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q3 2023.
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) has 96 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43,943,299 shares
of 54,711,345 outstanding shares and own 80% of the company stock.
Largest 10 shareholders include Skorpios Trust (14,443,681 shares), RTW INVESTMENTS, LP (4,390,558 shares), Redmile Group, LLC (3,872,696 shares), COWEN AND COMPANY, LLC (3,721,659 shares), MORGAN STANLEY (2,913,784 shares), BlackRock Inc. (2,206,510 shares), Lynx1 Capital Management LP (1,710,154 shares), VANGUARD GROUP INC (1,630,688 shares), BAKER BROS. ADVISORS LP (1,485,915 shares), and Cormorant Asset Management, LP (1,087,807 shares).
This table shows the top 96 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.